Application of umbilical cord mesenchymal stem cells (MSCs) in the acute myocardial infarction cell transplantation therapy

A technology for acute myocardial infarction and stem cells, which is applied in the field of biomaterials in the medical field, can solve the problems of poor medical compliance, increased medical expenses, differentiation and proliferation of autologous stem cells, and reduced para/autocrine function, and achieves the effect of improving prognosis.

Active Publication Date: 2010-02-10
PLA NAVY GENERAL HOSIPTAL
View PDF1 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the urgent problems to be solved in cell therapy of acute myocardial infarction are: ①The differentiation and proliferation of autologous stem cells and the decrease of para-autocrine function in patients with coronary heart disease and elderly patients cannot achieve effective biological effects; ②The best time window for AMI cell transplantation is infarction-related blood vessels 4-6 days after reconstitution, and the preparation time of autologous bone

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of umbilical cord mesenchymal stem cells (MSCs) in the acute myocardial infarction cell transplantation therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Preparation of UW-MSCs transplantation material - using fresh UW-MSCs

[0022] Fresh umbilical cord Huatong jelly mesenchymal stem cells that have just been subcultured for 2-4 generations were digested with 0.05-0.25% trypsin for 1-5 minutes, serum was neutralized, washed 3 times with balanced salt solution, and the centrifugal force of the centrifuge was controlled. In 100-1000g, the "10-20 unit heparin / ml 0.9% sodium chloride" injection should be resuspended for use.

Embodiment 2

[0023] Example 2 Preparation of UW-MSCs Transplantation Materials—Using Cryopreserved UW-MSCs Standbys

[0024] Take out the frozen 2-4 generation umbilical cord Huatong jelly mesenchymal stem cells from the cryogenic container, quickly put them into a 35-38°C incubator and water bath, dissolve within 2 minutes, and resuspend the cells with complete medium solution. After 2-4 days of cell fusion, re-digest and wash the cells, add heparin sodium chloride injection to make the cell concentration 1-2×10 6 / ml of cell suspension, usually packed in 10ml tubes. Wherein the heparin sodium chloride injection used for suspending cells preferably has a ratio of: 1000 units of heparin: 100 ml of normal saline.

experiment example 1U

[0025] Experimental example 1 UW-MSCs in vitro and in vivo differentiation into cardiomyocytes and functional identification

[0026] Purified 3rd generation UW-MSCs were marked with DAPI staining and then induced to differentiate with 5-azacytidine. Immunofluorescence staining was performed 2 weeks later. It was detected under a confocal microscope that the DAPI-positive UW-MSCs could differentiate into cardiomyocyte phenotype characteristics. Cardiomyocyte-like cells co-expressed with DAPI: troponin (TnT), actin (a-actin), GATA-4, connexin-43. Further in vivo, on the acute myocardial infarction model in rats, the green fluorescent protein gene (EGFP) was transfected into UW-MSCs as UW-MSCs markers, and 1×10 6UW-MSCs-EGFP was injected around the infarcted myocardium of rats, frozen sections of myocardial tissue were detected by immunofluorescence confocal microscopy after 4 weeks, and it was found that transplanted UW-MSCs labeled with EGFP in the original infarcted myocardiu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of umbilical cord mesenchymal stem cells (MSCs) in the acute myocardial infarction cell transplantation therapy; the application is suitable for ST-segment elevation acute myocardial infarction within one mouth or non ST-segment elevation acute myocardial infarction cases, a vascular remodeling is carried out to a patient who is attacked by the disease withinsix hours, after about four to six days, coronary perfusion is carried out to the patient; and the other patients who choose date to carry out vascular remodeling operation, the coronary perfusion iscarried out at the same time. The treating effect in the invention is superior to the bone mesenchymal stem cells transplantation.

Description

technical field [0001] The invention relates to the use of biological materials in the medical field, in particular to the application of mesenchymal stem cells prepared from human umbilical cord Huatong jelly in the preparation of cell transplantation materials for treating acute myocardial infarction. Background technique [0002] Coronary heart disease is a disease that seriously endangers human life and health. In China alone, more than 5 million people die from coronary heart disease every year, and among them, those who die from acute myocardial infarction (AMI) account for a considerable proportion. In recent years, the development of vascular reconstruction techniques such as direct interventional surgery and drug thrombolysis has improved the early prognosis of AMI. However, evidence-based medicine has confirmed that early vascular reconstruction can only save ischemic stunned myocardium, but cannot prevent necrotic myocardium from being destroyed. Non-contractile f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/12A61P9/10C12N5/08A61K35/28
Inventor 高连如张宁坤陈宇杨晔丁青艾朱智明曹毅
Owner PLA NAVY GENERAL HOSIPTAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap